Brief: Can-Fite Reports Survival Benefits Of Namodenoson For Patients With Advanced Liver Cancer

Can Fite Biopharma

28/12/2022 12:18

Dec 28 (Reuters) - Can Fite Biopharma Ltd  CANF.TA :
    * CAN-FITE UPDATES: NAMODENOSON INCREASES SURVIVAL FOR THE
MOST
SEVERE PATIENTS WITH ADVANCED LIVER CANCER
    * CAN FITE BIOPHARMA LTD - RECEIVED AGREEMENT FROM BOTH U.S.
FDA
AND EMA ON ITS PHASE III PIVOTAL LIVER CANCER STUDY WHICH IS NOW
OPEN FOR ENROLLMENT

Source text for Eikon:  ID:nBw8xHkjSa 
Further company coverage:  CANF.TA 
 ((Reuters.Briefs@thomsonreuters.com;))